Impact of platelet transfusion on toxicity and mortality after hematopoietic progenitor cell transplantation
暂无分享,去创建一个
H. Atkins | D. Allan | L. Huebsch | S. Mcdiarmid | A. Tinmouth | C. Bredeson | W. Petrcich | A. Giulivi | J. Tay | D. Sheppard | M. Sabloff | I. Bence-Bruckler | N. Kekre | E. Saidenberg | D. Neurath | M. Tokessy | G. Christou
[1] E. Wood,et al. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. , 2013, The New England journal of medicine.
[2] A. Ho,et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study , 2012, The Lancet.
[3] S. Hopewell,et al. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. , 2012, The Cochrane database of systematic reviews.
[4] D. Allan,et al. Storage time of transfused red blood cells and impact on clinical outcomes in hematopoietic stem cell transplantation , 2011, Transfusion.
[5] E. Vamvakas. COMMENTARY: Relative safety of pooled whole blood–derived versus single‐donor (apheresis) platelets in the United States: a systematic review of disparate risks , 2009, Transfusion.
[6] T. Hervig,et al. A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. , 2009, Blood.
[7] Neil Blumberg,et al. The platelet as an immune cell—CD40 ligand and transfusion immunomodulation , 2009, Immunologic research.
[8] D. Allan,et al. Reduced hemoglobin on day of peripheral blood progenitor cell collection is associated with low graft content of vascular progenitors and increased toxicity after autologous hematopoietic stem cell transplantation , 2008, Transfusion.
[9] N. Heddle,et al. Comparing the efficacy and safety of apheresis and whole blood–derived platelet transfusions: a systematic review , 2008, Transfusion.
[10] C. Ramos,et al. Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation , 2007, Bone Marrow Transplantation.
[11] Edward J. Lee,et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. , 2005, Blood.
[12] F. Frassoni,et al. Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft‐versus‐host disease, donor type, cytomegalovirus infections and cell dose , 2001, British journal of haematology.
[13] J. Vose,et al. A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. , 1998, Blood.
[14] F. Appelbaum,et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] S. Moore,et al. Diagnostic and pathogenetic considerations in transfusion‐related acute lung injury , 1985, Transfusion.